Exosomal Expression of CXCR4 Targets Cardioprotective Vesicles to Myocardial Infarction and Improves Outcome after Systemic Administration by Ciullo, Alessandra et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2019
Exosomal Expression of CXCR4 Targets Cardioprotective Vesicles to
Myocardial Infarction and Improves Outcome after Systemic Administration
Ciullo, Alessandra ; Biemmi, Vanessa ; Milano, Giuseppina ; Bolis, Sara ; Cervio, Elisabetta ; Fertig,
Emanuel Tudor ; Gherghiceanu, Mihaela ; Moccetti, Tiziano ; Camici, Giovanni G ; Vassalli, Giuseppe ;
Barile, Lucio
Abstract: Cell therapy has been evaluated to enhance heart function after injury. Delivered cells mostly
act via paracrine mechanisms, including secreted growth factors, cytokines, and vesicles, such as exo-
somes (Exo). Intramyocardial injection of cardiac-resident progenitor cells (CPC)-derived Exo reduced
scarring and improved cardiac function after myocardial infarction in rats. Here, we explore a clinically
relevant approach to enhance the homing process to cardiomyocytes (CM), which is crucial for thera-
peutic efficacy upon systemic delivery of Exo. By overexpressing exosomal CXCR4, we increased the
efficacy of plasmatic injection of cardioprotective Exo-CPC by increasing their bioavailability to ischemic
hearts. Intravenous injection of Exo significantly reduced infarct size and improved left ventricle ejection
fraction at 4 weeks compared to Exo ( < 0.01). Hemodynamic measurements showed that Exo improved
dp/dt min, as compared to Exo and PBS group. In vitro, Exo was more bioactive than Exo in preventing
CM death. This in vitro effect was independent from SDF-1￿, as shown by using AMD3100 as specific
CXCR4 antagonist. We showed, for the first time, that systemic administration of Exo derived from
CXCR4-overexpressing CPC improves heart function in a rat model of ischemia reperfusion injury These
data represent a substantial step toward clinical application of Exo-based therapeutics in cardiovascular
disease.
DOI: https://doi.org/10.3390/ijms20030468
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-173422
Journal Article
Published Version
 
 
The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0)
License.
Originally published at:
Ciullo, Alessandra; Biemmi, Vanessa; Milano, Giuseppina; Bolis, Sara; Cervio, Elisabetta; Fertig, Emanuel
Tudor; Gherghiceanu, Mihaela; Moccetti, Tiziano; Camici, Giovanni G; Vassalli, Giuseppe; Barile, Lu-
cio (2019). Exosomal Expression of CXCR4 Targets Cardioprotective Vesicles to Myocardial Infarction
and Improves Outcome after Systemic Administration. International Journal of Molecular Sciences,
20(3):E468.
DOI: https://doi.org/10.3390/ijms20030468
2
 Int. J. Mol. Sci. 2018, 19, 468; doi:10.3390/ijms20030468 www.mdpi.com/journal/ijms 
Article 
Exosomal Expression of CXCR4 Targets 
Cardioprotective Vesicles to Myocardial Infarction and 
Improves Outcome after Systemic Administration 
Alessandra Ciullo 1,2, Vanessa Biemmi 1, Giuseppina Milano 1,3, Sara Bolis 1, Elisabetta Cervio 1, 
Emanuel Tudor Fertig 4, Mihaela Gherghiceanu 4, Tiziano Moccetti 1, Giovanni G. Camici 2,†, 
Giuseppe Vassalli 1,2,5,† and Lucio Barile 1,*,† 
1 Cellular and Molecular Cardiology Laboratory, Cardiocentro Ticino Foundation, 6900 Lugano, 
Switzerland; alessandra.ciullo@cardiocentro.org (A.C.); vanessa.biemmi@cardiocentro.org (V.B.); 
giuseppina.milano@cardiocentro.org (G.M.); sara.bolis@cardiocentro.org (S.B.); betta.cervio@gmail.com 
(E.C.); tiziano.moccetti@cardiocentro.org (T.M.); giuseppe.vassalli@cardiocentro.org (G.V.) 
2 Molecular Cardiology Institute, Department of Cardiology, University of Zürich, 8952 Schlieren, 
Switzerland; giovanni.camici@uzh.ch 
3 Laboratory of Cardiovascular Research, Lausanne University Hospital, 1011 Lausanne, Switzerland 
4 “Victor Babes” National Institute of Pathology, 050096 Bucharest, Romania; fertig.e@gmail.com (E.T.F.)., 
mgherghiceanu@yahoo.com (M.G.) 
5 Faculty of Biomedical Science, University of Italian Switzerland, 6900 Lugano, Switzerland 
* Correspondence: lucio.barile@cardiocentro.org; Tel.: +41-91-805-3384 
† These authors contributed equally to this work. 
Received: 8 January 2019; Accepted: 20 January 2019; Published: 22 January 2019 
Abstract: Cell therapy has been evaluated to enhance heart function after injury. Delivered cells 
mostly act via paracrine mechanisms, including secreted growth factors, cytokines, and vesicles, 
such as exosomes (Exo). Intramyocardial injection of cardiac-resident progenitor cells (CPC)-
derived Exo reduced scarring and improved cardiac function after myocardial infarction in rats. 
Here, we explore a clinically relevant approach to enhance the homing process to cardiomyocytes 
(CM), which is crucial for therapeutic efficacy upon systemic delivery of Exo. By overexpressing 
exosomal CXCR4, we increased the efficacy of plasmatic injection of cardioprotective Exo-CPC by 
increasing their bioavailability to ischemic hearts. Intravenous injection of ExoCXCR4 significantly 
reduced infarct size and improved left ventricle ejection fraction at 4 weeks compared to ExoCTRL (p 
< 0.01). Hemodynamic measurements showed that ExoCXCR4 improved dp/dt min, as compared to 
ExoCTRL and PBS group. In vitro, ExoCXCR4 was more bioactive than ExoCTRL in preventing CM death. 
This in vitro effect was independent from SDF-1α, as shown by using AMD3100 as specific CXCR4 
antagonist. We showed, for the first time, that systemic administration of Exo derived from CXCR4-
overexpressing CPC improves heart function in a rat model of ischemia reperfusion injury These 
data represent a substantial step toward clinical application of Exo-based therapeutics in 
cardiovascular disease. 
Keywords: exosomes; CXCR4; cardiac progenitor cells; intravenous injection 
 
1. Introduction 
Over the past 20 years, cell-therapy approaches have been investigated as an exciting strategy 
to repair heart tissue after myocardial infarction (MI) [1–3]. Today the prevailing view is that stem 
and progenitor cells elicit their therapeutic effects via indirect paracrine mechanisms that result in 
the salvage of myocardium at risk, rather than cardiac regeneration by trans-differentiating into 
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cardiomyocytes (CM) [1,4]. This notion implies that therapeutic agents, including cells and cell-
derivatives, such as extracellular vesicles (EV), act within the context of cardioprotection, and it 
would ideally be delivered as early as possible after acute MI [4]. In patients after acute MI, 
intracoronary (IC) or systemic delivery of bio-therapeutics at very early time points, soon after the 
percutaneous coronary angioplasty (for instance, as it has been implemented with systemic 
thrombolysis) [5], would be desirable to achieve cardioprotection, while also minimizing the risk of 
intramyocardial (IM) injections using a percutaneous catheter.  
Recently data pointed to exosomes (Exo), nanosized EV formed into cytosolic sub-compartments, 
as the main indirect mechanism of benefit of cardiac progenitor cells (CPCs) and other cell types, such 
as bone marrow-derived mesenchymal stem cells (MSCs), into infarcted hearts [6–10]. Exo are 
composed of a phospholipidic bilayer that encloses proteins, nucleic acids (mRNA, DNA, microRNA), 
and lipids [11,12], which mediate a variety of intercellular signals [13,14]. In a porcine model of 
chronic MI, Exo-CPC were shown to promote neovascularization and to decrease infarct size 
following IM, but not IC administration [15]. It was hypothesized that these differences between the 
two routes of administration might be due to limited Exo retention in the heart after IC delivery [15]. 
This raises the question on how to enhance Exo homing to injured myocardium. 
CXCL12 (also known as stromal cell-derived factor 1; SDF-1α) is a member of the CXC 
chemokine family, which is overexpressed in ischemic tissues [16,17], including infarcted 
myocardium. The expression of this chemokine in infarcted myocardium is upregulated because the 
activation of hypoxia-induced factor-1(HIF-1) [18]. It has been shown that SDF-1α plasma levels are 
increased in patients post-MI [17]. SDF-1α binds the CXCR4 receptor, acting as a potent 
chemoattractant for CXCR4 expressing cells, including circulating progenitor cells [19]. This effect by 
SDF-1α play a role in cardiac repair through the recruitment of circulating progenitor cells to the 
infarct zone [20,21]. To maximize the effect of SDF-1α for tissue regeneration, several groups have 
genetically engineered MSCs to overexpress CXCR4, which resulted in enhanced MSC mobilization, 
engraftment, and cardiac repair in vivo [22–24]. Kang K et al. showed that using an in vivo rat MI 
model, a cell sheet of MSCs primed with Exo overexpressing CXCR4 (ExoCXCR4) was able to preserve 
heart function when applied soon after coronary artery ligation, whereas the MSC sheet exposed to 
control Exo was ineffective. These results indicated that MSC-derived ExoCXCR4 enhance MSC-
mediated cardioprotection [25]. The in vivo direct effect of ExoCXCR4 by intravenous injection has not 
yet been tested. In our design, we propose a systemic delivery of Exo rather than Exo-mediated 
priming of injectable cells. To address this question, we engineered CPCs to overexpress CXCR4 
(CPCCXCR4). Although CPC share with MSC the expression of well-known surface markers, such as 
CD105, CD90, CD73, Exo secreted by CPC resulted deeply different in terms of protein content and 
functional properties compared to Exo-MSC [6]. Having recently described the cardioprotective 
activities of IM injected Exo-CPC in a rat MI model [6], here we explored whether CPCCXCR4 –derived 
Exo exhibit superior homing and cardioprotective effects, as compared to naturally occurring Exo 
injected via tail-vein. We hypothesized that the formation of an SDF-1α gradient towards the heart 
following MI might increase the bioavailability and the retention of ExoCXCR4 within the tissue. 
Particularly, we evaluated the therapeutic efficacy of systemic ExoCXCR4 administration in an acute 
model of ischemia/reperfusion (I/R). I/R model has recently been indicated as the most appropriate 
preclinical model for studying cardioprotective strategies [26]. Additionally Exo homing to, and 
uptake by, CM was studied ex vivo in isolated-perfused hearts. Finally, we also sought to confirm 
their cardioprotective properties in human iPS-derived CM. 
2. Results 
2.1. CPCCXCR4 Load Exogenous Receptor into Exo at Protein and mRNA Levels 
Although primary naïve CPC express the transmembrane receptor CXCR4 (CD184), this is 
poorly expressed on the surface of Exo secreted by these cells. Therefore, we used PCMV3-Cx-Myc 
plasmid in an attempt at enriching cells and Exo for hCXCR4 receptor. Transfection significantly 
Int. J. Mol. Sci. 2018, 19, 468; doi:10.3390/ijms20030468  3 of 24 
3 
 
increased expression of CXCR4 in cells (CPCCXCR4) in comparison to CPC transfected with empty 
backbone (CPCCTRL), as verified by flow-cytometer (FC) and western blot (WB) analyses (Figure 1a,b). 
CXCR4 could be detected on Exo secreted by CPCCXCR4 (ExoCXCR4) and slightly onto surface of Exo 
derived from CPCCTRL (ExoCTRL) (Figure 2a,b). The level of expression of CXCR4 in ExoCTRL was 
comparable to naïve expression of this receptor with no increment due to the transfection of backbone 
plasmid (Figure A1e). 
 
Figure 1. The hCXCR4 expression. (a) Flow cytometer analyses for relative expression of hCXCR4 
(CD184) in control CPC (CPCCTRL, purple histogram), and CXCR4 overexpressing CPC (CPCCXCR4, blue 
histogram). Quantitative data are percentage of positive cells (n = 6 patients/group) * p < 0.05 (two-
tailed, paired Student t-test). (b) Western blot showing expression of CXCR4 in CPCCTRL vs. CPCCXCR4. 
Quantitative data are relative expression levels (densitometry) of CXCR4 normalized for β-actin and 
showed as fold-changes to CPCCTRL (n = 6 patients/group) * p < 0.05 (two-tailed, paired Student t-test). 
To verify the correct transmembrane orientation of the receptor in ExoCXCR4, FC analysis was 
performed using two different antibodies directed against both the N-terminus (extraluminal-
domain) and the C-terminus (intraluminal-domain) region in the absence of permeabilization. Only 
the anti-N-terminus CXCR4 antibody resulted in a positive staining (Figure 2c). Data was confirmed 
by Cryo Electron Microscopy (Cryo-EM) analysis and immunogold staining experiment, using anti-
CXCR4 (N-terminus) as a primary antibody (Millipore) (Figure 2d). 
In order to determine the presence of endogenous versus exogenous CXCR4 mRNA in Exo, we 
constructed 2 primer pairs that specifically amplified the hCXCR4 sequence only (pairs 1,2, Figure 
A1) and the hCXCR4 sequence with the fused c-Myc tag (pairs 1–3, Figure 2e). The hCXCR4 mRNA 
was slightly detectable in ExoCTRL and dramatically increased in ExoCXCR4. Only ExoCXCR4 contained the 
exogenous sequence as evidenced by the presence of the c-Myc tag amplicon (Figure 2e). By WB 
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analysis, ExoCTRL and ExoCXCR4 expressed similar levels of the Exo specific marker TSG-101 (Figure 2b), 
and tetraspanins (CD63, CD9, CD81) by FC analysis (Figure 2f). The expression of functional 
pregnancy-associated plasma protein-A (PAPP-A), previously showed to be functional into Exo-CPC 
[6], was similar in ExoCTRL and ExoCXCR4 (Figure A1d). Moreover, the overexpression of CXCR4 does 
not impair size/concentration distributions of Exo, as assessed by Nanosight analysis (Figure 2g). 
 
Figure 2. CXCR4 expression. (a) Quantitative data flow cytometer analyses for relative expression of 
CXCR4 in ExoCTRL (purple bar), and CXCR4 overexpressing Exo (ExoCXCR4, blue bar). Exo were bound 
to beads before analyses as described in the method section. Data are fold-changes in mean 
fluorescence intensity (MFI) versus controls (n = 7 patients/group) * p < 0.05 (two-tailed, paired 
Student t-test). (b) Western blot showing expression of CXCR4 in ExoCXCR4 vs. ExoCTRL. Quantitative 
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data are relative expression levels of CXCR4 normalized for TSG101 and showed as fold-changes to 
ExoCTRL (n = 4 patients/group). (c) Bead-based flow cytometric analysis for Exo. Two different 
antibodies directed against the N-terminus (extraluminal-domain) and the C-terminus (intraluminal-
domain) region of hCXCR4 (CD184) were used in the absence of permeabilization. Only the anti-N-
terminus CXCR4 antibody resulted in a positive staining, as shown by the right-shift of bead-Exo 
complex. (d) Cryo-EM image of ExoCXCR4 immunolabeled with rabbit CXCR4 as a primary Ab, and 
goat-anti-Rabbit IgG 25 nm gold conjugate as a secondary Ab, showing CXCR4 on the surface of a 
particle. (e) The hCXCR4-mRNA expression. Conventional RT-PCR showing the presence of hCXCR4 
mRNA in Exo. The exogenous sequence (c-Myc) is only present into ExoCXCR4. Primers used for 
individual PCR assays, are indicated by numbers in brackets in the Appendix Figure 1. (f) Expression 
of the exosome markers, CD9, CD63, and CD81, as assessed by flow cytometry in ExoCTRL purple dots), 
and ExoCXCR4 (blue dots). (g) Size distribution of Exo. Averaged Size/Concentration of ExoCTRL (n = 10 
repeated measurements of 3 different patients) and ExoCXCR4 (n = 10 repeated measurements of 3 
different patients). Red error bars indicate +/− SE of the mean. 
2.2. Intravenous Injection of ExoCXCR4, but not ExoCTRL, Is Protective after In Vivo I/R Injury 
Since our experimental hypothesis was based on the important role of the CXCR4-SDF-1αaxis 
in cardiac repair, we empirically assessed the SDF-1α levels into myocardial tissue at different time-
points following myocardial I/R injury (Figure A2). The chemokine was picked at three h after 
reperfusion; this time-point was chosen for the in vivo tail vein injection of Exo (Figure 3a). ExoCXCR4, 
but not ExoCTRL, improved left ventricular ejection fraction (LVEF) at 7 days (Figure 3b). Both types 
of Exo significantly improved LVEF at 4 weeks, as compared to PBS-injected control rats (75.0 ± 1.4% 
and 63.5 ± 2.5% for ExoCXCR4 and ExoCTRL, respectively, versus 53.7 ± 1.1% in the PBS group; p < 0.01 
and p < 0.05 respectively). ExoCXCR4 was significantly more effective than ExoCTRL in this regard (p < 
0.01). Parallel changes in end-systolic and end-diastolic LV volumes were observed (Figure 3c,d). 
Hemodynamic measurements showed that ExoCXCR4 significantly improved –dp/dt min. Although 
not statistically significant, a trend toward the dp/dt max improvement was also observed in ExoCXCR4 
group. ExoCTRL improved –dp/dt min only slightly, as compared to the PBS group (Figure 3e). From 
LV pressure/volume loops, the time constant of isovolumic LV pressure fall (Tau) properties was 
significantly reduced in hearts injected with ExoCXCR4. The whole set of hemodynamic data indicated 
a global improved in diastolic relaxation (Figure 3f) for hearts injected with ExoCXCR4. Finally, hearts 
in the ExoCXCR4 group displayed smaller scars than those in the ExoCTRL or PBS groups (Figure 4a). 
There also was a significant reduction of scar size in the ExoCTRL group vs. PBS. Both ExoCTRL and 
ExoCXCR4 increased blood vessel density (Figure 4b) at a similar level.  
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Figure 3. In vivo cardio-protection after I/R. (a) Scheme depicting the study protocol. I/R model was 
induced by ligating the left descending anterior coronary that was then released after 30 min. Exo (2 
× 1011 total particles from a pool of n = 6 patients, in 300 μL PBS) were injected tail vein 3 h after 
reperfusion. (b) ExoCXCR4 but not ExoCTRL significantly improved LVEF at 7days after I/R, compared to 
PBS control group. At 28 days after I/R, ExoCXCR4, and to a lesser extent ExoCTRL, significantly improved 
LVEF compared to control group (n = 6 rats/group), # p < 0.05 (one-way analyses of variance-ANOVA 
with post-hoc multiple comparisons using the Tukey-Kramer multiple comparisons test for paired 
parametric comparisons; test was performed at each time-point). (c,d) ExoCTRL reduced both left 
ventricle (LV) end-systolic volume (LVESV) and left ventricle end-diastolic volume (LVEDV) was 
significantly less than modified Exo CXCR4 (n = 6 rats/group), # p < 0.05 (one-way analyses of variance-
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ANOVA with post-hoc multiple comparisons using the Tukey-Kramer multiple comparisons test for 
paired parametric comparisons; test was performed at each time-point). (e) Hemodynamic 
measurements showing a decreased ventricular compliance in the ExoCXCR4 by quantitative analysis 
of –dp/dt min and dp/dt max (n = 6 rats/group for ExoCTRL and ExoCXCR4; n = 5 rats/group PBS) # p < 
0.05 (one-way analyses of variance-ANOVA with post-hoc multiple comparisons using the Tukey-
Kramer multiple comparisons test for paired parametric comparisons; test was performed at each 
time-point). (f) From LV pressure/volume loops, the time constant of isovolumic LV pressure fall (Tau) 
value, which reflects diastolic relaxation properties, was calculated. LV relaxation was improved and 
time constant reduced in the ExoCXCR4 (n = 6 rats/group) group compared with the ExoCTRL (n = 6 rats 
/group) and PBS (n = 5 rats/group) # p < 0.05 (one-way analyses of variance-ANOVA with post-hoc 
multiple comparisons using the Tuke–Kramer multiple comparisons test for paired parametric 
comparisons;). 
 
Figure 4. (a) Masson’s Trichrome staining for the quantification of infarct size. Exo reduce scar size at 
28 days after I/R. The reduction in scar size is more pronounced in ExoCXCR4 compared to ExoCTRL 
treated group (n = 5 rats/group PBS, n = 6 rats/group ExoCTRL and ExoCXCR4). (b) ExoCTRL and Exo CXCR4. 
increased blood vessel density. SMA, smooth muscle actin (green); TnI, Troponin I (red); nuclear 
counterstaining (blue); n = 4 rats/group PBS, n = 6 rats/group ExoCTRL and ExoCXCR4). # p < 0.05 (one-
way analyses of variance-ANOVA with post-hoc multiple comparisons using the Tukey–Kramer 
multiple comparisons test for paired parametric comparisons). 
2.3. ExoCXCR4 Is Delivered More Efficiently than ExoCTRL to CM in Ischemic/Reperfused Rat Hearts Ex Vivo 
To assess whether the superior in vivo cardioprotective effect of ExoCXCR4 is mediated by 
increased cardiac homing as a result of SDF-1α upregulation in the injured heart, rat hearts were 
subjected to in vivo I/R injury. Three hours later, hearts were harvested and perfused retrogradely in 
a Langendorff-mode (Figure 5a). Equal amounts of ExoCXCR4celmiR39 or ExoCTRLcelmiR39 (see section 4) were 
added to the perfusates in the two groups, and hearts were continuously perfused for 2 h. CM were 
then isolated from hearts perfused ex vivo, and cel-miR39 levels were determined in the isolated CM 
as a measure of Exo delivery. ExoCXCR4celmiR39 perfused hearts showed increased cel-miR39 levels 
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compared with both ExoCTRLcelmiR39 and PBS-perfused control hearts (fold-increase vs. PBS: 162.6 ± 42.6 
and 7.7 ± 1.7 for ExoCXCR4celmiR39 and ExoCTRLcelmiR39 respectively; Figure 5b). In addition, hCXCR4/c-Myc 
mRNA was detectable in adult CM from hearts perfused with ExoCXCR4celmiR39, but not in those 
receiving ExoCTRLcelmiR39 (Figure 5c). These results indicate that following in vivo I/R injury ExoCXCR4 is 
delivered to CM in injured hearts more efficiently than ExoCTRL. 
 
Figure 5. Cellular uptake of Exo by rat adult CM. (a) Experimental design. I/R model was induced in 
rat and 3 h later hearts were excided and retrogradely perfused in a langendorff system for a 
subsequent 2 h. ExoCTRLcel-miR39 and ExoCXCR4cel-miR39 were added to the perfusates. PBS was added to the 
control perfusing solution. (a) ExoCXCR4cel-miR39 containing perfusates showed increased cel-miR39 
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levels compared with ExoCTRLcel-miR39 and PBS perfused control hearts. Data are 2−ΔΔCt values vs. PBS-
perfused hearts (n = 5 patients/group) # p < 0.05 (two-tailed, paired Student t-test). (b) Western blotting 
analyses on cell lysate of isolated adult CM. The levels of ERK1/2 phosphorylation was increased into 
CM ExoCXCR4cel-miR39 from isolated rat hearts. (c) TUNEL staining. TUNEL-positive (green nuclei) of 
apoptotic CM (α-SA -positive cells; red). The α-SA mask is used to detect nuclei within CM on DAPI 
fluorescence. Quantitative data are expressed as number of green on total CM nuclei, # p < 0.05 (one-
way analyses of variance-ANOVA with post-hoc multiple comparisons using the Tukey-Kramer 
multiple comparisons test for paired parametric comparisons). 
2.4. ExoCXCR4 Shows Superior Ex Vivo Cardioprotective Effects Compared with ExoCTRL 
Having previously showed that Exo act mostly through MAP kinases pathway[6], we evaluated 
whether ERK1/2 phosphorylation was improved in adult CM isolated from ex vivo experiments. CM 
isolated from infarcted and perfused hearts were lysed for WB analysis. ExoCXCR4celmiR39 was able to 
significantly induce ERK1/2 phosphorylation after 2 h of perfusion as compared to PBS perfused 
hearts (Figure 5b), whereas ExoCTRLcelmiR39 was less effective in this regard. 
To confirm cytoprotective role of Exo a subset of isolated adult CM were plated on glass 
coverslip and soon after fixed for TUNEL staining. Both ExoCTRLcelmiR39 and ExoCXCR4celmiR39 increased 
the number of surviving CM after 2 h of perfusion as compared to PBS group. The number of adult 
CM undergoing apoptosis was lower in ExoCXCR4 than ExoCTRL, although not statistically significant 
(Figure 3c). 
2.5. ExoCXCR4 Shows Superior In Vitro Cardioprotective Effects Compared with ExoCTRL 
ExoCTRL is cytoprotective in neonatal HL-1 [6,7]; here we compared its cytoprotective activity 
with that of ExoCXCR4 using the in vitro model of staurosporine-induced death in HL-1 cardiomyocytes. 
ExoCXCR4 was more effective than ExoCTRL in preventing staurosporine-induced death in HL-1 cells 
(ExoCXCR4 94.7 ± 2.6%; ExoCTRL 80.9 ± 1.8%) (Figure 6a,b). Similar results were obtained in human iPSC-
derived CM, as ExoCXCR4 was more effective than ExoCTRL at preventing staurosporine-induced death 
in these cells (ExoCXCR4 73.0 ± 2.7%; ExoCTRL 58.6 ± 1.2%; Figure A3). Furthermore, the effect of ExoCXCR4 
in HL-1 cells was not antagonized by ADM3100, indicating that is was independent from SDF-1α 
(Figure 6c). Similar intracellular levels of celmiR39 was observed in normal or stress conditions when 
ExoCXCR4celmiR39 and ExoCTRLcelmiR39 were added to the media of HL-1 cells; indicating that the presence 
of CXCR4 on Exo surface did not increase in vitro uptake (Figure 6d). This finding is probably related 
to the absence of an SDF-1α gradient in this in vitro model, as opposed to the in vivo situation, as 
shown by WB in vitro analysis (Figure A2b). Both ExoCTRL and ExoCXCR4 induced ERK1/2 
phosphorylation after staurosporine-induced damage. Compared with ExoCTRL, ExoCXCR4 treated HL-
1 showed higher levels of phosphorylated ERK1/2 in both staurosporine-induced (Figure 7a) and 
normal (Figure A4c) conditions. The effect was prevented by adding the kinases chemical inhibitor 
U0126 (Figure 7b). In parallel, U0126 was able to abolish ExoCXCR4 protective effect on HL-1 CM 
(Figure 7d). This finding is in line with our previous data [6], showing that the ERK pathway is 
involved in the anti-apoptotic effect mediated by Exo. 
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Figure 6. In vitro bioactivities of ExoCXCR4. (a,b) ExoCTRL, and ExoCXCR4 inhibit staurosporine-induced 
death in HL-1 CM (green) (n = 6 patients/group for ExoCTRL and ExoCXCR4; n = 5 repeated measurements 
for PBS and FBS) # p < 0.01 (one-way analyses of variance-ANOVA with post-hoc multiple 
comparisons using the Tukey-Kramer multiple comparison tests for paired parametric comparisons). 
ExoCXCR4 exhibit superior pro-survival effect. (c) ExoCXCR4 superior pro-survival effect in HL-1 CM is 
not affected by the addition of AMD3100 as specific CXCR4 antagonist. (d) In vitro Exo uptake. Real-
time PCR analyses of cel-miR39 (mature sequence) levels in HL1 CM incubated with ExoCTRLcel-miR39 
and ExoCXCR4cel-miR39 during normal or stress conditions. Data are 2−ΔΔCt values vs. PBS (n = 5 
patients/group). 
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Figure 7. (a) Western blot showing pro-survival ERK1/2 phosphorylation in HL-1 CM when ExoCTRL, 
and ExoCXCR4 were added to the medium in stress-conditions (n = 4 patients/group) # p < 0.01 (Kruskal-
Wallis test nonparametric multiple comparisons with Dunn’s multiple comparison test); * p < 0.05 
(two-tailed, paired Student t-test). (b) ERK1/2 phosphorylation is prevented by adding the kinases 
chemical inhibitor U0126. (n = 5 patients/group for ExoCTRL and ExoCXCR4; n = 5 repeated measurements 
for PBS) # p < 0.01 (one-way analyses of variance-ANOVA with post-hoc multiple comparisons using 
the Tukey-Kramer multiple comparisons test for paired parametric comparisons). (c) Human 
recombinant SDF-1α is able to stimulate CXCR4 receptor in mouse HL-1 CM only after these cells 
have uptaken the human receptor from Exo (n = 5 patients/group); * p < 0.05 (two-tailed, paired 
Student t-test). (d) Exo CXCR4 are significantly less effective in preventing staurosporine cell death when 
HL1 CM are treated with the kinases chemical inhibitor U0126, (n = 5 patients/group for ExoCXCR4 and 
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ExoCXCR4+U0126; n = 4 repeated measurements for PBS ) # p < 0.05 (one-way analyses of variance-
ANOVA with post-hoc multiple comparisons using the Tukey-Kramer multiple comparisons test for 
paired parametric comparisons). Cell vitality was not affected by U0126 alone (n = 4 repeated 
measurements). 
2.6. ExoCXCR4 Transfers CXCR4 mRNA and Protein into CM In Vitro 
We hypothesized that the superior cytoprotective in vitro effect of ExoCXCR4 was due to the 
transfer of bioactive CXCR4 to target cells that may enhance the previously described cytoprotective 
effect of Exo (which also includes PAPP-A mediated protease activity) [6]. We tested the presence of 
exogenous hCXCR4 in murine HL-1 CM at mRNA and protein levels. The hCXCR4-mRNA was 
detected in HL-1 CM exposed to ExoCXCR4 but not in those exposed to ExoCTRL. Moreover, the c-Myc 
nucleic acid sequence within the hCXCR4-c-Myc construct was detected by RT-PCR in cells exposed 
to ExoCXCR4 but not in those exposed to ExoCTRL (Figure A4a). This observation was made both under 
basal conditions and after staurosporine-induced cell stress (Figure A4a). The c-Myc tag was 
detectable at the protein level in CM treated with ExoCXCR4, demonstrating the translation of the 
hCXCR4-c-Myc fusion construct, but not in those receiving ExoCTRL (Figure A4b). These results 
demonstrate the ability of ExoCXCR4 to deliver the mRNA encoding for the exogenous hCXCR4, which 
may result in the translation of hCXCR4 protein in mouse CM. Because hCXCR4 bioactivity requires 
the presence of SDF-1α [18], we used a species-specific human recombinant SDF-1α protein (hDF-1α) 
that does not activate the downstream ERK signal in mouse HL-1 cells in order to assess hCXCR4 
bioactivity in these cells (Figure 7c). HL-1 cells pre-treated with ExoCXCR4, but not pre-treated with 
ExoCTRL, exhibited increased ERK1/2 phosphorylation after the subsequent exposure to hDF-1α 
(Figure 7c). These results indicate that ExoCXCR4 delivers bioactive hCXCR4 to target cells. 
3. Discussion 
Exo have emerged as a therapeutic tool with the potential to replace cellular approaches in the 
treatment of cardiovascular disease [6,7,27–28]. Compared with cell therapy, Exo offer several 
potential advantages, as they can be stored at −80 °C without a substantial loss of functional activity 
[6,7,29], they are effective after systemic delivery [30], with a dosage that is not limited by 
microvascular plugging [31], and they are poorly immunogenic [32]. With respect to therapeutic 
applications, safety and efficacy of Exo depend on their bio-distribution that influence selective and 
effective uptake, respectively, by target cells after systemic delivery [33]. In fact, a given Exo is taken 
up with different efficiencies by different recipient cell types [34]. Systemically delivered Exo is 
largely up taken by the liver, and to lesser extents by spleen and lungs [35–37], although in vivo Exo 
bio-distribution also depends on the producing cell type [12]. In animal models of ischemic heart 
disease, IM Exo administration was beneficial in several studies [6–8], whereas IC Exo administration 
was tested in a single study [15]. The latter found that IM delivered Exo from CPCs, but not IC 
delivered Exo from the same producing cells were beneficial in a pig MI model, mainly due to 
comparatively lower Exo retention in the heart using the IC route of administration. From a 
translational perspective, IM Exo injection would hardly be feasible for treating acute MI patients, 
thus, improving Exo retention by the heart after IC or systemic administration is a crucial goal. 
Recently studies have attempted to engineer transmembrane proteins of Exo using “cardiac-homing 
peptide” to increase targeting capability to cardiac tissues [38–40]. These study showed that homing 
peptides displayed on the external part of Exo, although not directly implicated into mechanism of 
action of Exo, promote the specificity and efficiency of systemic delivery of Exo. 
Our experimental approach leverages on the important role of the CXCR4-SDF-1α axis in cardiac 
repair. SDF-1α is markedly upregulated within 1 h of myocardial ischemia, resulting in a 
chemoattractant gradient for CXCR4 expressing leukocytes and stem cells [41]. Within the heart, SDF-
1α expression was demonstrated for both CM and fibroblasts a few hours after acute MI [41]. In light 
of the above, we hypothesized that beside the physiological ischemia-induced cardiac SDF-1α 
expression, overexpressing CXCR4 in Exo would result in an enhanced homing of Exo to the injured 
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myocardium, and thus, increased cardioprotective effects. To test this hypothesis, we genetically 
modified CPCs to overexpress CXCR4 and then isolated the secreted Exo. CXCR4 was detectable on 
ExoCXCR4 but not on ExoCTRL released from naive CPCs. Exo homing to, and uptake by, CM was studied 
ex vivo in isolated-perfused hearts after in vivo I/R injury. ExoCXCR4 were markedly more effective 
than ExoCTRL in this regard. It should be emphasized that Exo uptake was specifically studied in CM 
isolated from ischemic rat hearts, as opposed to the total heart cell population. We did not evaluate 
and discriminate Exo uptake by other cell types within the ischemic heart, such as fibroblast and 
endothelial cells. This represents a limitation of the study, however, we have evidence showing that 
the benefit of ExoCXCR4 and its superior effect as compared to ExoCTRL results in an increased number 
of surviving cardiomyocytes (Figures 4a and 5c) rather than improved angiogenesis (Figure 4b), for 
which we did not find any significant difference between the groups. Exo uptake measured here 
includes both homing to I/R heart tissue and CM binding and uptake. These different components of 
the global “uptake” process cannot be discriminated. For instance, enhanced Exo homing to injured 
myocardium would increase Exo bioavailability in the extracellular compartment, and therefore on 
the CM surfaces, and result in an increase in total Exo uptake by CM, even in the case when the 
intrinsic Exo uptake efficiency (i.e., the intrinsic efficiency of the process at a single particle level) was 
unaffected. In vivo, we similarly found superior functional benefits in terms of scar size as well as LV 
systolic and diastolic function for ExoCXCR4 compared with ExoCTRL. Efficient ExoCXCR4 homing to I/R 
myocardium, as demonstrated in ex vivo isolated-perfused hearts, most likely played an important 
role in vivo, too.  
Although the increased concentration of SDF-1α cytokine within the heart tissue may enhance 
bio-availability of Exo in close proximity of CM surface, it does not have a direct effect in mediating 
the uptake in vitro, where the experimental conditions failed to recapitulate in vivo cytokines 
gradient (Figure 6a). Indeed, the use of a specific CXCR4 antagonist (AMD3100) has no effect on 
increasing Exo uptake, neither inhibits protection, in vitro. On the other hand, the transfer of active 
and SDF-1α-responsive receptor from Exo to target cells, as shown in the Figure 7c, plays a crucial 
role leading to activation of protective signaling pathways, and in addition is of the already described 
mechanisms via PAPP-A–mediated IGF-1 release [6]. As expected, the degree of Exo-mediated 
improvement of cardiac function, previously shown by our group upon IM injection into infarcted 
hearts [6], could not be matched by the tail-vein injection, likely due to larger in vivo biodistribution. 
Indeed, at seven days after tail-vein injection of ExoCTRL we did not achieve statistically significant 
improvement compared to saline group (Figure 7), as was the case by IM injection in previous studies 
[6,7]. By enhancing homing of Exo to CM via CXCR4 expression on the vesicle surface, we achieved 
comparable functional improvements using IM and systemic routes of administrations (Figure 3). 
Previous studies have shown that mesenchymal stem cells (MSCs) overexpressing surface CXCR4 
improve migration and engraftment in response to SDF-1α gradients in various disease models [42–
44]. Taking a methodological approach similar to the one used here, Kang et al. [25] recently showed 
that Exo secreted from CXCR4 overexpressing MSCs mediated antiapoptotic and proangiogenic 
effects in vitro, while also indirectly enhancing MSC-mediated CM survival in vivo. 
Here, we investigated for the first time the direct effects of systemic ExoCXCR4 injection and 
established Exo homing/uptake as a crucial mechanism by which CXCR4 increases Exo-CPC delivery 
to CM. ExoCXCR4 not only transfer their exogenous protein to the target cells, they are also able to 
transfer the mRNA, and this confirmed data obtained from different groups [45]. The relative 
contribution of bioactive CXCR4 versus the transduction of its mRNA by Exo receiving cells has not 
been detailed in the present study. From the functional point of view, ExoCXCR4 have superior in vitro 
and in vivo anti-apoptotic effects in CM compared to ExoCTRL. These results have major translational 
implications for treatment of acute MI patients, owing to the major advantages associated with 
systemic drug administration [25], which can be performed upon recanalization of the culprit artery. 
4. Materials and Methods 
4.1. Cell Culture 
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Right cardiac atrial appendage specimens were obtained from patients (n = 13) who underwent 
surgical repair of heart valve disease and gave written informed consent. Protocols used in this study 
were approved by local Ethical Committee for Clinical Research (Comitato Etico Cantonale, 
Bellinzona, Switzerland; Rif. CE 2923), and study was performed according to the Declaration of 
Helsinki. CPCs were derived from atrial specimens, as described [6]. Briefly, atrial specimens were 
cultured as primary ex vivo tissue explants in basic Iscove’s modified Dulbecco’s medium (IMDM; 
Lonza, Basel, Switzerland) supplemented with 20% fetal bovine serum (FBS) and 1% v/v penicillin-
streptomycin (Life Technologies, Europe BV, Zug, Switzerland). The cellular outgrowth of atrial 
explants was collected within 14 days and seeded into fibronectin-coated 25 mL flasks, forming a 
monolayer of CPCs that were passaged twice by trypsinization before Exo purification from 
conditioned media. Mouse HL-1 cardiomyocyte cell line (LSU Health Sciences Center, New Orleans, 
LA, USA) was grown in Claycomb Medium (Sigma, Merck KGaA, Darmstadt, Germany) 
supplemented with 100 μM norepinephrin, 10% FBS, 1% v/v penicillin/streptomycin, and 4 mM L-
glutamine [46]. AMD3100 (Millipore, Merck KGaA) at the concentration of 10 μM was used as specific 
CXCR4 antagonist. For experiments performed to establish the bioactivity of human CXCR4 into 
target cells (Figure 7c), confluent HL-1 were treated with human recombinant SDF-1α chemokine 
(hDF-1α, Sigma) at the concentration of 100 ng/mL for 40 min. The kinases chemical inhibitor U0126 
monoethanolate (Sigma) at the concentration of 20 μM was used to inhibit ERK1/2 phosphorylation; 
iPS-derived CM were obtained as previously described [45]. Briefly CPC were reprogrammed 
through Sendai virus infection using OCT3/4, SOX2, KLF4, and MYC (CytoTune™-iPS 2.0 Sendai 
Reprogramming Kit; Thermo Fisher Scientific, Europe BV, Zug, Switzerland), according to 
manufacturer’s instructions. Cardiac differentiation of iPSCs was induced using the GibcoTM PSC 
Cardiomyocyte Differentiation Kit (Thermo Fisher Scientific). Differentiated cells were maintained in 
RPMI (Gibco, Thermo Fisher Scientific) supplemented with B27 (Gibco) at 37 °C and 5% of CO2 and 
changed every two days. 
4.2. CPC Engineering to Overexpress CXCR4 
The human sequence of CXCR4 (NM_001008540) was cloned into PCMV3-C-Myc expression 
plasmid (Sino Biological Inc., Wayne, PA, USA) to encode the hCXCR4 cDNA fused with c-Myc tag 
under the transcriptional control of a CMV promoter (PCMV3-Cx-Myc). This vector was used to 
transfect CPCs (CPCCXCR4). Control CPC (CPCCTRL) were transfected with an empty backbone plasmid. 
Briefly, CPCs were gently collected by trypsinization and re-suspended in normal growth medium 
at the density of 1 × 105 cells/mL. The transfection agent Lipofectamine 3000 was diluted in Opti-MEM 
I medium (both from Thermo Fisher Scientific) and left for 10 min at RT. PCMV3-Cx-Myc plasmid or 
empty backbone were diluted in Opti-MEM I medium and P3000 reagent (2 μL/μg DNA). After 
incubation, the mix with Lipofectamine 3000 Reagent was added to the mix, containing the diluted 
plasmid and incubated for an additional 10 min at RT. The mixture was then gently rocked and 
incubated at 37 °C, 5% CO2. Two days after transfection, cells were washed several times with PBS 
and the growth medium was exchanged with Exo-producing medium (DMEM high-glucose, Thermo 
Fisher Scientific). 
4.3. Particle Purification 
Media conditioned by CPCCTRL and CPCCXCR4 were obtained by culturing cells in Exo-producing 
medium in absence of serum for 7 days [6]. For particle purification, conditioned medium (10 mL) 
was centrifuged at 3000 g for 15 min, filtered through a 0.2 μm membrane (BD Biosciences, Allschwil, 
Switzerland), centrifuged at 10000 g for 15 min, and then ultracentrifuged at 100000 g for 4 h. Exo 
pellets were re-suspended in 100 μL PBS, pH 7.4, and stored at −80 °C. Particle number and size were 
measured using NanoSight technology (Malvern Instruments, Malvern, UK).  
4.4. Flow Cytometry 
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CPCCTRL and CPCCXCR4 were labelled with phycoerythrin (PE)-conjugated antibody anti-CXCR4 
(CD184) (eBioscience, Thermo Fisher Scientific) and analyzed by means of direct 
immunofluorescence with a Cytoflex flow cytometer (Beckman Coulter, Nyon, Switzerland). Isotype-
matched, nonreactive fluorochrome-conjugated antibodies were used as controls. Surface antigen 
markers expressed on Exo were analyzed as described [6]. Briefly, exosomes were incubated with a 
mix of microbeads coated with anti-CD63, anti-CD9, and anti-CD81 and anti-EPCAM antibody (JSR), 
and then with fluorochrome-conjugated Abs against CD63, CD9, CD81 (all from BD Biosciences), and 
anti-CXCR4 (CD184) extracellular (Alomone, Jerusalem, Israel) or anti-CXCR4 intraluminal (Abcam, 
Cambridge, UK). Beads incubated with in the absence of Exo served as controls. The resulting data 
were processed using Kaluza™ analysis software (Beckman Coulter, Nyon, Switzerland).  
4.5. Immuno-Gold Labeling and Cryo-Electron Microscopy(Cryo-EM) 
For cryo-EM, isolated exosomes were resuspended in 30 mM HEPES, pH 7.4, containing 100 mM 
KCl. Immuno-gold labelling was done by successive incubations of the exosome solution with 1:10 
anti-CXCR4 antibody (Millipore) overnight, at 4 °C, then with 1:25 of either 15 and/or 25 nM gold-
conjugated goat Anti-Rabbit secondary antibodies (Aurion), for 3 h, at room temperature. A 4–5 μL 
drop was deposited on glow-discharged 200-mesh copper grids with 2 μm holes (Quantifoil R2/2, 
Quantifoil Micro Tools, Großlöbichau, Germany), then plunged frozen in liquid ethane using a Leica 
EM-GP (Leica Microsystems, Wetzlar, Germany), at 90% humidity. For examination, all grids were 
transferred under liquid nitrogen to a Gatan 626 cryo-holder (Gatan). Imaging was done under low-
dose conditions (~10 e- per Å2) by means of a 4k × 4k Ceta camera, on a FEI Talos 200C S/TEM (FEI 
Company), operated at 200 keV. Images were acquired at nominal magnifications of 36,000× and 
45,000×, and at 3 to 5 μm underfocus, giving a final object sampling of 4.1 and 3.2 Å per pixel, 
respectively. 
4.6. Protein Isolation and Western Blot Analyses 
Total proteins were extracted by lysing Exo or cells with ice-cold RIPA buffer (25 mM Tris pH 
7.4, 150 mM NaCl, 1 mM EDTA, 1% Igepal CA 630, 1% Na-deoxycholate, 0.01% sodium dodecyl 
sulfate; SDS) supplemented with protease inhibitors (SIGMAFAST™ Protease Inhibitor Tablets; 
Sigma) for 30 min at 4 °C under agitation. Exosome and cell lysates were centrifuged at 9500 g for 15 
min at 4 °C, and protein concentrations were determined using the BCA kit (Sigma). Proteins were 
boiled with Laemmli SDS sample buffer 6× (0.375M Tris-HCl pH 6.8, 12% SDS, 60% glycerol, 0.6 M 
DTT, 20% (v/v) β-mercaptoethanol, 0.2% (w/v) bromophenol blue; VWR International, Dietikon, 
Switzerland), separated on 4–20% Mini-PROTEAN® TGX™ Precast Gel (Bio-Rad Europe, Basel, 
Switzerland), and transferred onto a PVDF membrane with a semi-dry transfer system (Bio-Rad 
Europe). The membranes were first blocked for 1 hr in Odyssey Blocking Buffer (LI-COR Biosciences, 
Bad Homburg vor der Höhe, Germany) diluted 1:1 in distilled water and supplemented with 0.2% 
Tween 20 (OBB-T), then incubated with the appropriate primary Ab diluted in OBB-T at 4 °C 
overnight under gentle agitation. The membranes were rinsed and then incubated with an IRDye® 
680RD or 800CW goat anti-mouse or goat anti-rabbit secondary Ab (LI-COR Biosciences; 1:15000 
dilution in OBB-T) at RT for 2 h. The infrared signal was detected using the Odyssey CLx Detection 
System (LI-COR Biosciences). Anti-TSG101 rabbit monoclonal Ab (1:1000) was from Abcam; anti-
CXCR4 rabbit polyclonal Ab (1:1000) was from Millipore, anti-β-actin mouse monoclonal HRP-
conjugated Ab (1:25000) was from Sigma, anti p-ERK, anti total ERK rabbit polyclonal Ab (1:1000) 
were from Cell Signalling, anti-SDF1-α rabbit polyclonal (1:1000), and anti-GAPDH rabbit polyclonal 
(1:1000) were from Abcam. For the evaluation of ERK1/2 phosphorylation in adult CM isolated from 
ex vivo perfused hearts, total proteins were extracted by lysing adult CM with ice-cold RIPA buffer 
supplemented with protease inhibitors for 30 min at 4 °C under agitation. Western Blot analysis was 
performed using the protocol described previously. Antibodies anti p-ERK, anti-total ERK rabbit 
polyclonal Ab (1:1000) were used. The homodimeric active form of PAPP-A was specifically 
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measured by dot immunoblotting under non-denaturing conditions using mouse monoclonal 4PD4-
PAPP30 antibody (HyTest, Turku, Finland). 
4.7. In Vitro and Ex Vivo Exo Uptake by CM 
To assess in vitro and ex vivo cellular uptake of Exo by CM, both CPCCXCR4 and CPCCTRL were 
transfected with a pre-miRNA precursor for cel-miR-39 (Thermo Fisher Scientific), a C. elegans 
miRNA not present in mammalian cells. Intracellular cel-miR39 levels can be used as a measure of 
cellular uptake of cel-miR39 containing exosomes. Exo released from these cells are referred hereby 
as Exo CXCR4celmiR39 (from CPCCXCR4) and Exo CTRLcelmiR39 (from CPCCTRL). In vitro HL-1 were incubated 
with Exo CXCR4celmiR39 or Exo CTRLcelmiR39. CTRLcelmiR39 in normal conditions or after treatment with 
staurosporine. Ex vivo isolated rat hearts were perfused in a Langendorff-mode using perfusates 
supplemented with Exo CXCR4celmiR39 or Exo CTRLcelmiR39, and cel-miR-39 levels were measured in HL-1 
and primary adult rat CM using real-time RT-PCR. The level of expression cel-miR39 in the CPC or 
Exo was consistent with dose-response efficiencies of transfection [6].  
4.8. Levels of Exogenous mRNA into CM 
PCR was performed using 2 pairs primers that specifically amplified the hCXCR4 sequence only 
or the hCXCR4 sequence fused with c-Myc tag (1,2 for human CXCR4-mRNA; 1–3 c-Myc-mRNA; see 
scheme in Figure A1). The murine sequence of CXCR4 receptor was not amplified by primers (Figure 
A4), thus allowing the identification of mRNA carried by human derived Exo (hCXCR4-mRNA), or 
overexpressed CXCR4 (c-Myc-mRNA). 
4.9. In Vitro CM Viability Assay 
To assess HL-1 CM viability, cells were seeded at a 6.25 × 104 cells/cm2 density in 96-well plates. 
After 24 h, cell death was induced by 1μM staurosporine (Sigma). ExoCTRL or ExoCXCR4 (isolated from 
conditioned media of cells from n = 6 patients) were added on top of staurosporine at the 3 × 106 
particles/cm2 concentration, as assessed by Nanosight [6]. In some of the tested conditions, the role 
of SDF-1α was tested by adding AMD3100 (10 μM) as CXCR4 specific antagonist. Twelve hours later, 
cells were stained with Cellstain™ Double Stain Kit (Dojindo EU, München, Germany) for 30 min at 
37 °C and counted under a fluorescence microscope. 
Functional data were validated in human iPS-derived CM. Cell death was induced in iPS-CM 
by 1 μM staurosporine (Sigma). ExoCTRL or ExoCXCR4 (isolated from conditioned media from n = 5 
patients) were added on top of staurosporine at the 3 × 106 particles/cm2 concentration, as assessed 
by Nanosight. Twelve hours later, cells were stained with Cellstain™ Double Stain Kit (Dojindo) for 
30 min at 37 °C and counted under a fluorescence microscope. 
4.10. RNA Extraction, Reverse Transcription and Real-Time PCR 
Cells or exosomes were lysed with TRI Reagent (Sigma), and chloroform was added following 
company instructions. The pellet was air-dried, re-suspended in DEPC water, and quantified with 
NanoDrop™ 2000c (Thermo Fisher Scientific). For real-time amplification of cel-miR-39 sequence, 
5ng of specific RNA was reverse-transcribed using the Taqman miRNA reverse stem-loop primers 
(Applied Biosystems, München, Germany) with a T100 Termal Cycler (Bio-Rad). Real-time PCR for 
specific cell-miR-39 sequence was performed by adding to 1.33 μL cDNA: 1 μL 20× specific primer 
(Applied Biosystems), 10 μL TaqMan Universal PCR Master Mix, and 7.67 μL DEPC water. 
Amplification and detection of specific products were performed in triplicate using a CFX Connect™ 
Real-Time PCR Detection System (Bio-Rad). Negative controls were included in each RT-PCR assay. 
The threshold cycle (Ct) of each gene was automatically defined and normalized to the control miR16 
(ΔCt value) for CPCs, HL-1 CM and exosomes, and to the control U87 or snoRNU202 for rats primary 
CM. Data are shown as 2−ΔΔCt values. 
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For PCR amplification of hCXCR4 mRNA sequences, 500 ng of total RNA was reverse 
transcribed using the GoScript™ Reverse Transcription System (Promega Madison, Dübendorf, 
Switzerland). Before use for PCR, reactions samples were diluted 1:2 in DEPC water. PCR was 
performed by adding to 2 μL cDNA, 4μL specific primer mix (1 μL primer forward:1 μL primer 
reverse:1 μL DEPC water), 5 μL 5× Green Reaction buffer, 0.5 μL 10 mM dNTPs mix, and 0.125 μL 
Taq enzime. Samples were incubated at 95 °C for 2 min, 95 °C for 30 s and 60 °C for 30 s, 72 °C for 1 
min, for 35 cycles. The following couple of primers were used: endogenous human CXCR4 forward: 
5-TCTGTGAGCAGAGGGTCCAG-3; reverse: 5-GCTGGAGTGAAAACTTGAAGACT-3. Exogenous 
human CXCR4-c-Myc forward 5-TCTGTGAGCAGAGGGTCCAG-3 reverse: 5-
TCCTCTTCTGAGATGAGTTTCT-3. 
4.11. Immunofluorescence and Histology 
Cells were fixed with paraformaldehyde 4%, sucrose 2%, permeabilized with 0.5% Triton for 30 
min and blocked with 5% serum for 30 min at 25 °C. Samples were then incubated with primary 
antibodies in 5% serum direct against CXCR4 (Abcam 1/100), c-Myc tag (Abcam 1/200) overnight at 
4 °C. After 3× wash with PBS, each 10 min, Alexa Fluor secondary antibodies (Life Technologies, 
1/1000) were used for detection. Images were acquired by a confocal microscopy system C2 Plus 
(Nikon). Harvested hearts were cryo-preserved in optimal cutting temperature (OCT) medium at 
−80°C. For morphometric analysis, hearts were cut in 8-μm sections, and stained with Masson- 
trichrome (HT15 Trichrome Stain Kit; Sigma) for measurement of scar size. On each heart section, 
scar area was determined by tracing the infarct borders manually using ImageJ software (NIH Image, 
Bethesda, MD, USA). Six sections distributed at fixed steps from the cardiac basis to the apex were 
analyzed for each heart and values were averaged. Anti-SMA (1:100) (Santa Cruz, CA, USA), smooth 
muscle actin, was used to stain vessels and TnI (1:100) (Santa Cruz, Santa Cruz, USA), Troponin I, as 
marker for CM, on each heart section. The number of vessels and surface area were quantified using 
ImageJ software. Six sections for each rat were used for the analysis and values were averaged. 
4.12. SDF-1α ELISA 
To assess the amount of SDF-1α protein on heart tissues of infarcted rats compared to control, 
ELISA Kit for rat SDF1/CXCL12 was used (LS Bio, Seattle, WA, USA). Briefly, samples were directly 
immobilized on to the wells of the microtiter plate. The detection (primary) antibody was added to 
the wells for binding to its specific antigen for 1 h at 37 °C. After 3 washes, the Detection (secondary) 
Ab was added and plate incubated for 30 min at 37 °C. A colorimetric substrate (Extra-sensitive TMB) 
was used for the assay read-out. The accumulation of the coloured product is proportional to the 
specific antigen present in each well. The results were quantitated with a microtiter plate reader at 
450 nm absorbance. 
4.13. TUNEL Assay 
Adult CM isolated from ex vivo experiments were plated on glass coverslips and fixed with 
paraformaldehyde 4%, permeabilized with 0.2% Triton for 5 min, and equilibrate at room 
temperature for 5–10 min with Equilibration Buffer. Samples were then incubated with a solution of 
Nucleotide Mix and rTdT Enzyme in a humidified chamber for 1 h at 37 °C and immersed in 2× SSC 
for 15 min at room temperature to terminate the reactions. After three washes to remove 
unincorporated fluorescein-12-dUTP, cells were incubated with a primary antibody against alpha 
sarcomeric actinin (1:100) and subsequently with an anti-mouse secondary antibody 568 (1:1000), 
both from Abcam and with DAPI, and immediately analyzed under a fluorescence microscope. A 
positive control slide using DNase I was included in each experiment.  
4.14. Animal Experiments 
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Experimental protocols were approved by the Animal Care Committee of Canton Ticino, 
Switzerland (TI-08-18). All procedures conformed to the Directive 2010/63/EU of the European 
Parliament. A model of myocardial ischemia with reperfusion was used. Ischemia Reperfusion (I/R) 
was induced in healthy male Wistar rats (250–300 g body weight) anesthetized with a cocktail of 
Ketamine (Ketasol 100, 100 mg/kg) and Xylazine (Rompun 2%, 80 mg/kg), intubated and ventilated. 
The left anterior descending artery was ligated near its origin with a 6-0 prolene suture. The coronary 
ligature was released after 30 min, and exosomes were injected in the tail-vein 3h after reperfusion 
with a total of 300 μL of PBS containing 2 × 1011 particles of the following vesicle populations: pool of 
Exo-CPCCTRL (n = 6) and pool of Exo-CPCCXCR4 (n = 6) or PBS. The chest was then closed, pneumothorax 
was reduced, and the rats were treated with Meloxicam during postsurgical recovery. Sedated rats 
underwent transthoracic echocardiography at 7 and 28 days post-MI using the Vevo2100 
echocardiography system (VisualSonic System 2100, FUJIFILM VisualSonics, Toronto, Canada) 
equipped with a 15-MHz linear transducer. Under ECG monitoring of heart rate, 2D images of the 
hearts were acquired in long-axis views at the level of the greatest LV diameter. LV ejection fraction 
(LVEF) was measured using Simpson’s analysis.  
Hemodynamic analysis was performed at day 28 using a Millar pressure-volume conductance 
catheter. Rats were anesthetized with an intraperitoneal injection of ketamine (Ketasol 100, 100 mg/kg) 
and xylazine (Rompun 2%, 80 mg/kg). The trachea was cannulated, and the animal connected to a 
positive- pressure volume-controlled rodent ventilator. The catheter was introduced through the 
right carotid artery into the ascending aorta and then into the LV cavity. After hemodynamics 
measurements, the animal was sacrificed. 
4.15. Statistical Analyses 
Results are presented as means ± SE of n independent experiments or patients from which Exo 
producing cells were derived. Each single “n” is specified in the figure legends. Statistical analyses 
were performed using InStat, version 3.0 (GraphPad Software, Inc., San Diego, CA, USA). The 
hypothesis that data came from a normally distributed population was assessed using the 
Kolmogorov Smirnov normality test. The assumption that data were sampled from populations with 
identical SDs was tested using the method of Bartlett. The Student t-test was used to compare two 
normally distributed populations. One-way analyses of variance (ANOVA) with subsequent post-
hoc multiple comparisons using the Tukey–Kramer multiple comparisons test were used for 
parametric comparisons. The Kruskal–Wallis test was used for nonparametric multiple comparisons. 
To perform post-hoc pairwise comparisons following Kruskal–Wallis test, Dunn’s non-parametric 
multiple comparisons procedure was used. Differences with probability values p < 0.05 were 
considered statistically significant.  
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IMDM Iscove’s Modified Dulbecco’s Medium 
Exo-CPC Exosomes Produced by Cardiac-Resident Progenitor Cells 
HIF-1 Hypoxia-Induced Factor 1 
Exo Exosomes 
CPC Cardiac-Resident Progenitor Cells 
MSC Bone Marrow-Derived Mesenchymal Stem Cells 
Exo CXCR4 Exosomes Expressing CXCR4 
CPC CXCR4 Cardiac-Resident Progenitor Cells that Overexpress CXCR4 
FBS Fetal Bovine Serum 
CPC CTRL Control Cardiac-Resident Progenitor Cells 
Exo CTRL Exosomes Produced by Control Cardiac-Resident Progenitor Cells
SMA Smooth Muscle Actin 
TnI Troponin I 
MI Myocardial Infarction 
CM Cardiomyocyte 
EV Extracellular Vesicle 
IC Intracoronary 
IM Intramyocardial 
I/R Ischemia/Reperfusion 
FC Flow Citometry 
WB Western Blot 
PE Phycoerythrin 
Appendix A 
 
Figure A1. CXCR4-mRNA expression. (a) Conventional RT-PCR showing the presence of CXCR4 
mRNA in cells before and after transfection (CPCCTRL vs. CPCCXCR4). The exogenous sequence (c-Myc) 
is only present into transfected cells (CPCCXCR4). (b)The hCXCR4-mRNA is slightly present in ExoCTRL 
and its expression increases in Exo produced by transfected cells (ExoCXCR4). The sequence of c-Myc 
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tag is present in ExoCXCR4. (c) Representative PCR analyses on isolated adult CM from ex vivo 
experiments; the sequence of c-Myc tag is present in ExoCXCR4. Primers used for individual PCR assays 
are indicated by numbers in brackets, as for the top drawing. (d) Representative dot immunoblotting 
using 4PD4-PAPP30 mAb that selectively detects dimeric (active) PAPP-A, which was unchanged in 
naïve Exo, Exo derived from cell transfected with backbone plasmid (ExoCTRL) and Exo derived from 
cells overexpressing hCXCR4 (ExoCXCR4 ). (e) Representative western blotting analysis showing level 
of expression in Exo, ExoCTRL and ExoCXCR4. 
 
Figure A2. (a) Levels of SDF-1α detected by ELISA in rat heart tissue at 3 and 24 h post MI (n = 4 
rats/group for Sham; n = 5 rats/group for 3h and 24h) # p < 0.05 (one-way analyses of variance-ANOVA 
with post-hoc multiple comparisons using the Tukey-Kramer multiple comparisons test for paired 
parametric comparisons). (b) WB for SDF-1α on HL-1 cell lysate following staurosporine treatment. 
 
 
Figure A3. In vitro bioactivities of ExoCXCR4. (a) ExoCTRL, and ExoCXCR4 inhibit staurosporine-induced 
death in human iPS-derived CM (b) (n = 5 patients/group for ExoCTRL and ExoCXCR4; n = 4 repeated 
measurements for PBS and FBS) # p < 0.05 (one-way analyses of variance-ANOVA with post-hoc 
multiple comparisons using the Tukey-Kramer multiple comparisons test for paired parametric 
comparisons). 
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Figure A4. In vitro transfer of CXCR4 mRNA and protein into target cells. (a) The c-Myc-mRNA 
sequence is transferred by Exo into target cells in both physiological and stress conditions 
(staurosporine). (b) Immunofluorescence staining showing the presence of c-Myc-tag protein (white 
arrows) into adult CM isolated from heart perfused ex vivo with ExoCXCR4cellmiR39. For the wild-type 
CXCR4, protein cells have been stained with a primary anti-CXCR4 antibody, which recognizes 
human and rat protein. (c) Phosphorylation of ERK1/2 is enhanced in HL-1 CM after treatment with 
ExoCXCR4 (n = 5 patients/group for ExoCTRL and ExoCXCR4; n = 5 repeated measurements for PBS ) # p < 
0.05 (one-way analyses of variance-ANOVA with post-hoc multiple comparisons using the Tukey-
Kramer multiple comparisons test for paired parametric comparisons).  
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